The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals,
  a start-up run by a former hedge fund manager [Shkreli]. Turing immediately
  raised the price to $750 a tablet from $13.50, bringing the annual cost of
  treatment for some patients to hundreds of thousands of dollars.